Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Chemical Communications (Cambridge, England)|December 7, 2007
Picosecond infrared probing of the vibrational spectra of transients formed upon UV excitation of stacked G-tetrad structuresDavid A McGovern, Susan Quinn, Gerard W Doorley, et al.
Trials|March 14, 2024
Efficacy of a virtual reality-based cognitive interactive training program for children with traumatic brain injuries: study protocol for a parallel-group randomized controlled trialJiabin Shen, Yan Wang, Susan Quinn, et al.
Chemical Communications (Cambridge, England)|May 24, 2007
Ultrafast IR spectroscopy of the short-lived transients formed by UV excitation of cytosine derivativesSusan Quinn, Gerard W Doorley, Graeme W Watson, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancersHelena A Yu, Myung-Ju Ahn, Byoung Chul Cho, et al.
Future Oncology (London, England)|July 18, 2019
Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancerJesús Corral, Tony S Mok, Kazuhiko Nakagawa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancerLecia V Sequist, Benjamin Besse, Thomas J Lynch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2008
Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancerGunnar Folprecht, Josep Tabernero, Claus-Henning Köhne, et al.
Journal of Medicinal Chemistry|December 23, 2009
Design and synthesis of novel diaminoquinazolines with in vivo efficacy for beta-catenin/T-cell transcriptional factor 4 pathway inhibitionChristoph M Dehnhardt, Aranapakam M Venkatesan, Zecheng Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2009
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumorsKwok-K Wong, Paula M Fracasso, Ronald M Bukowski, et al.
Pageof 2